Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study

Author： Schaapveld Michael   Vries Elisabeth   Graaf Winette   Otter Renée   Willemse Pax  

Publisher： Springer Publishing Company

ISSN： 0171-5216

Source： Journal of Cancer Research and Clinical Oncology, Vol.130, Iss.10, 2004-10, pp. : 581-590

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer

By Ananda Sumitra   Steer Christopher  

The Women's Oncology Review, Vol. 5, Iss. 2, 2005-06 ,pp. : 109-111

Informa Healthcare

Access to resources Recommend Favorite

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer

By Colleoni M.   Price K.   Castiglione-Gertsch M.   Goldhirsch A.   Coates A.   Lindtner J.   Collins J.   Gelber R.D.   Thurlimann B.   Rudenstam C.M.  

European Journal of Cancer, Vol. 34, Iss. 11, 1998-10 ,pp. : 1693-1700

Elsevier

Access to resources Recommend Favorite

A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up

By Walshe Janice   Berman Arlene   Vatas Ujala   Steinberg Seth   Anderson William   Lippman Marc   Swain Sandra  

Breast Cancer Research and Treatment, Vol. 103, Iss. 2, 2007-06 ,pp. : 177-183

Springer Publishing Company

Access to resources Recommend Favorite

Survival analyses from the ZEBRA study - goserelin (Zoladex(TM)) versus CMF in premenopausal women with node-positive breast cancer

By Kaufmann M.   Jonat W.   Blamey R.   Cuzick J.   Namer M.   Fogelman I.   de Haes J.C.   Schumacher M.   Sauerbrei W.   on behalf of the Zoladex Early Breast Cancer Research Association ZEBRA Trialists' Group  

European Journal of Cancer, Vol. 39, Iss. 12, 2003-08 ,pp. : 1711-1717

Elsevier

Access to resources Recommend Favorite

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

By Amadori Dino   Silvestrini Rosella   Lena Mario   Boccardo Francesco   Rocca Andrea   Scarpi Emanuela   Schittulli Francesco   Brandi Mario   Maltoni Roberta   Serra Patrizia   Ponzone Riccardo   Biglia Nicoletta   Gianni Lorenzo   Tienghi Amelia   Valerio Maria   Bonginelli Paola   Amaducci Laura   Faedi Marina   Baldini Editta   Paradiso Angelo  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 775-784

Springer Publishing Company

Access to resources Recommend Favorite